Details of the Drug Formulations

General Information of Drug (ID: DMVM6QR)

• Drug Name: Lacosamide Drug Info
• Synonyms: Erlosamide; Harkoseride; Vimpat; Erlosamide [INN]; Lacosamide [USAN]; ADD 234037; SPM 927; ADD-234037; SPM-927; SPM-929; Erlosamide, Vimpat, Lacosamide; Lacosamide (USAN/INN); (2R)-2-(Acetylamino)-N-benzyl-3-methoxypropanamide; (2R)-2-(acetylamino)-N-benzyl-3-methoxypropanamide; (2R)-2-acetamido-N-benzyl-3-methoxypropanamide

Indication

Disease Entry	ICD 11	Status	REF
Convulsion	8A68.Z	Approved	[1]
Epilepsy	8A60-8A68	Approved	[2]
Diabetic neuropathy	8C0Z	Phase 3	[1]

• Therapeutic Class: Analgesics
• Cross-matching ID:
  PubChem CID: 219078
  ChEBI ID: CHEBI:135939
  CAS Number: 175481-36-4
  TTD ID: D05OFX
  INTEDE ID: DR0911
  ACDINA ID: D00346

Full List of Drug Formulations Containing This Drug

Lacosamide 50 mg tablet

Company	Formulation ID	FDA Description
Physicians Total Care	F11028	Fd&c blue no. 2; Indigotindisulfonate sodium; Magnesium stearate; Ferric oxide red; Ferrosoferric oxide; Talc; Titanium dioxide; Crospovidone; Polyvinyl alcohol; Silicon dioxide; Aluminum oxide; Cellulose, microcrystalline; Hydroxypropyl cellulose; Hypromelloses; Polyethylene glycols
Natco Pharma	F11025	Fd&c blue no. 2; Magnesium stearate; Ferric oxide red; Ferrosoferric oxide; Talc; Titanium dioxide; Lecithin, soybean; Polyvinyl alcohol; Silicon dioxide; Cellulose, microcrystalline; Crospovidone (15 mpa.s at 5%); Hydroxypropyl cellulose; Hydroxypropyl cellulose, low substituted; Polyethylene glycols
Breckenridge Pharmaceutical	F11026	Fd&c blue no. 2; Magnesium stearate; Ferric oxide red; Ferrosoferric oxide; Talc; Titanium dioxide; Lecithin, soybean; Polyvinyl alcohol; Silicon dioxide; Cellulose, microcrystalline; Crospovidone (15 mpa.s at 5%); Hydroxypropyl cellulose (type h); Hydroxypropyl cellulose, low substituted; Polyethylene glycols
UCB	F11027	Fd&c blue no. 2; Indigotindisulfonate sodium; Magnesium stearate; Ferric oxide red; Ferrosoferric oxide; Talc; Titanium dioxide; Silicon dioxide; Aluminum oxide; Crospovidone (15 mpa.s at 5%); Hydroxypropyl cellulose (1200000 mw); Hypromellose, unspecified; Microcrystalline cellulose; Polyethylene glycol, unspecified; Polyvinyl alcohol, unspecified

Lacosamide 200 mg tablet

Company	Formulation ID	FDA Description
Natco Pharma	F11022	Fd&c blue no. 2; Magnesium stearate; Talc; Titanium dioxide; Lecithin, soybean; Polyvinyl alcohol; Silicon dioxide; Cellulose, microcrystalline; Crospovidone (15 mpa.s at 5%); Hydroxypropyl cellulose; Hydroxypropyl cellulose, low substituted; Polyethylene glycols
Breckenridge Pharmaceutical	F11023	Fd&c blue no. 2; Magnesium stearate; Talc; Titanium dioxide; Lecithin, soybean; Polyvinyl alcohol; Silicon dioxide; Cellulose, microcrystalline; Crospovidone (15 mpa.s at 5%); Hydroxypropyl cellulose (type h); Hydroxypropyl cellulose, low substituted; Polyethylene glycols
UCB	F11024	Fd&c blue no. 2; Indigotindisulfonate sodium; Magnesium stearate; Talc; Titanium dioxide; Silicon dioxide; Aluminum oxide; Crospovidone (15 mpa.s at 5%); Hydroxypropyl cellulose (1200000 mw); Hypromellose, unspecified; Microcrystalline cellulose; Polyethylene glycol, unspecified; Polyvinyl alcohol, unspecified

Lacosamide 150 mg tablet

Company	Formulation ID	FDA Description
Natco Pharma	F11019	Magnesium stearate; Ferric oxide red; Ferric oxide yellow; Ferrosoferric oxide; Talc; Titanium dioxide; Lecithin, soybean; Polyvinyl alcohol; Silicon dioxide; Cellulose, microcrystalline; Crospovidone (15 mpa.s at 5%); Hydroxypropyl cellulose; Hydroxypropyl cellulose, low substituted; Polyethylene glycols
Breckenridge Pharmaceutical	F11020	Magnesium stearate; Ferric oxide red; Ferric oxide yellow; Ferrosoferric oxide; Talc; Titanium dioxide; Lecithin, soybean; Polyvinyl alcohol; Silicon dioxide; Cellulose, microcrystalline; Crospovidone (15 mpa.s at 5%); Hydroxypropyl cellulose (type h); Hydroxypropyl cellulose, low substituted; Polyethylene glycols
UCB	F11021	Magnesium stearate; Ferric oxide red; Ferric oxide yellow; Ferrosoferric oxide; Talc; Titanium dioxide; Silicon dioxide; Crospovidone (15 mpa.s at 5%); Hydroxypropyl cellulose (1200000 mw); Hypromellose, unspecified; Microcrystalline cellulose; Polyethylene glycol, unspecified; Polyvinyl alcohol, unspecified

Lacosamide 100 mg tablet

Company	Formulation ID	FDA Description
Natco Pharma	F11017	Magnesium stearate; Ferric oxide yellow; Talc; Titanium dioxide; Lecithin, soybean; Polyvinyl alcohol; Silicon dioxide; Cellulose, microcrystalline; Crospovidone (15 mpa.s at 5%); Hydroxypropyl cellulose; Hydroxypropyl cellulose, low substituted; Polyethylene glycols
Breckenridge Pharmaceutical	F11018	Magnesium stearate; Ferric oxide yellow; Talc; Titanium dioxide; Lecithin, soybean; Polyvinyl alcohol; Silicon dioxide; Cellulose, microcrystalline; Crospovidone (15 mpa.s at 5%); Hydroxypropyl cellulose (type h); Hydroxypropyl cellulose, low substituted; Polyethylene glycols
RemedyRepack; UCB	F11016	Magnesium stearate; Ferric oxide yellow; Talc; Titanium dioxide; Silicon dioxide; Crospovidone (15 mpa.s at 5%); Hydroxypropyl cellulose (1200000 mw); Hypromellose, unspecified; Microcrystalline cellulose; Polyethylene glycol, unspecified; Polyvinyl alcohol, unspecified

References

• [1] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7472).
• [2] Antibodies and venom peptides: new modalities for ion channels. Nat Rev Drug Discov. 2019 May;18(5):339-357.